Influenza Vaccines Market Size & Share, Statistics Report 2024-2032

Influenza Vaccines Market – By Vaccine Type (Inactivated, Live Attenuated), Indication (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Flu Type (Seasonal, Pandemic), Age Group, Route of Administration, End-user, Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculations

1.4&nbsp;&nbsp;&nbsp; Data collection

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of influenza

3.2.1.2&nbsp;&nbsp;&nbsp;Rising government health initiatives and immunization programs

3.2.1.3&nbsp;&nbsp;&nbsp;Growing advancements in vaccine technology

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost associated with vaccine development

3.2.2.2&nbsp;&nbsp;&nbsp;Longer vaccine production timelines

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.5.1&nbsp;&nbsp;&nbsp; Supplier power

3.5.2&nbsp;&nbsp;&nbsp; Buyer power

3.5.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.5.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.5.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Vaccine Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Inactivated

5.3&nbsp;&nbsp;&nbsp; Live attenuated

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Quadrivalent

6.3&nbsp;&nbsp;&nbsp; Trivalent

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Technology, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Egg-based

7.3&nbsp;&nbsp;&nbsp; Cell-based

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Flu Type, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Seasonal

8.3&nbsp;&nbsp;&nbsp; Pandemic

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Pediatrics

9.3&nbsp;&nbsp;&nbsp; Adults

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2018 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; Injection

10.3&nbsp;&nbsp;&nbsp; Nasal spray

Chapter 11&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-User, 2018 &ndash; 2032 ($ Mn)

11.1&nbsp;&nbsp;&nbsp; Key trends

11.2&nbsp;&nbsp;&nbsp; Hospitals

11.2.1&nbsp;&nbsp;&nbsp; Public

11.2.2&nbsp;&nbsp;&nbsp; Private

11.3&nbsp;&nbsp;&nbsp; Clinics

11.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 12&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

12.1&nbsp;&nbsp;&nbsp; Key trends

12.2&nbsp;&nbsp;&nbsp; North America

12.2.1&nbsp;&nbsp;&nbsp; U.S.

12.2.2&nbsp;&nbsp;&nbsp; Canada

12.3&nbsp;&nbsp;&nbsp; Europe

12.3.1&nbsp;&nbsp;&nbsp; Germany

12.3.2&nbsp;&nbsp;&nbsp; UK

12.3.3&nbsp;&nbsp;&nbsp; France

12.3.4&nbsp;&nbsp;&nbsp; Spain

12.3.5&nbsp;&nbsp;&nbsp; Italy

12.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

12.4&nbsp;&nbsp;&nbsp; Asia Pacific

12.4.1&nbsp;&nbsp;&nbsp; China

12.4.2&nbsp;&nbsp;&nbsp; Japan

12.4.3&nbsp;&nbsp;&nbsp; India

12.4.4&nbsp;&nbsp;&nbsp; Australia

12.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

12.5&nbsp;&nbsp;&nbsp; Latin America

12.5.1&nbsp;&nbsp;&nbsp; Brazil

12.5.2&nbsp;&nbsp;&nbsp; Mexico

12.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

12.6&nbsp;&nbsp;&nbsp; Middle East and Africa

12.6.1&nbsp;&nbsp;&nbsp; South Africa

12.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

12.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 13&nbsp;&nbsp;&nbsp;Company Profiles

13.1&nbsp;&nbsp;&nbsp; AstraZeneca plc

13.2&nbsp;&nbsp;&nbsp; CSL Limited

13.3&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

13.4&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc

13.5&nbsp;&nbsp;&nbsp; Sanofi SA

13.6&nbsp;&nbsp;&nbsp; Emergent BioSolutions

13.7&nbsp;&nbsp;&nbsp; Sinovac Biotech Ltd.

13.8&nbsp;&nbsp;&nbsp; Novartis AG

13.9&nbsp;&nbsp;&nbsp; Gamma Vaccines Pty Ltd.

13.10&nbsp;&nbsp;&nbsp; Viatris Inc. 
&nbsp;

Influenza Vaccines Market

Get a free sample of this report